Abstract：
OBJECTIVE: To investigate the platelet-rich plasma (PRP) effectiveness in patients with a long-lasting postviral olfactory dysfunction (LPOD).
METHODS: Forty-three consecutive patients with a long-lasting postviral OD were prospectively recruited. The injection of 1 mL of PRP was carried out in both olfactory clefts. The pre- to 6-month post-PRP injection change in olfaction was assessed with the olfactory disorder questionnaire (ODQ) and the threshold, discrimination, and identification (TDI) tests.
RESULTS: Forty-three patients received bilateral PRP injections (24 females). The mean age of patients was 58.9 ± 16.8 years. The mean duration of LPOD was 8.7 years. The pre to 6-month post-injection mean TDI significantly improved from 10.3 ± 10.2 to 20.12 ± 12.07 (p = 0.001). The mean ODQ significantly decreased from 29.8 ± 13.0 to 23.4 ± 11.3 (p = 0.013). The average change of the TDI and the ODQ were 9.8 and 6.4, respectively. Age was inversely associated with the 6-month threshold score.
CONCLUSIONS: PRP appears to be a promising therapeutic strategy for long-lasting postviral OD. Our findings support the conduction of controlled randomized trial in this population of patients.
METHODS: Forty-three consecutive patients with a long-lasting postviral OD were prospectively recruited. The injection of 1 mL of PRP was carried out in both olfactory clefts. The pre- to 6-month post-PRP injection change in olfaction was assessed with the olfactory disorder questionnaire (ODQ) and the threshold, discrimination, and identification (TDI) tests.
RESULTS: Forty-three patients received bilateral PRP injections (24 females). The mean age of patients was 58.9 ± 16.8 years. The mean duration of LPOD was 8.7 years. The pre to 6-month post-injection mean TDI significantly improved from 10.3 ± 10.2 to 20.12 ± 12.07 (p = 0.001). The mean ODQ significantly decreased from 29.8 ± 13.0 to 23.4 ± 11.3 (p = 0.013). The average change of the TDI and the ODQ were 9.8 and 6.4, respectively. Age was inversely associated with the 6-month threshold score.
CONCLUSIONS: PRP appears to be a promising therapeutic strategy for long-lasting postviral OD. Our findings support the conduction of controlled randomized trial in this population of patients.
摘要：
目的：探讨富血小板血浆（PRP）对长期持续的病毒后嗅觉功能障碍（LPOD）患者的疗效。
方法：前瞻性招募了43例具有长期持续的病毒后OD的连续患者。在两个嗅沟中注射ImL的PRP。使用嗅觉障碍问卷（ODQ）和阈值评估PRP注射前至6个月后嗅觉变化，歧视,和识别（TDI）测试。
结果：43例患者接受双侧PRP注射（24名女性）。患者的平均年龄为58.9±16.8岁。LPOD的平均持续时间为8.7年。注射前至注射后6个月的平均TDI从10.3±10.2显着改善为20.12±12.07（p=0.001）。平均ODQ从29.8±13.0显著降低至23.4±11.3(p=0.013)。TDI和ODQ的平均变化分别为9.8和6.4。年龄与6个月阈值得分呈负相关。
结论：PRP似乎是一种有希望的治疗策略，用于长期持续的病毒后OD。我们的发现支持在该患者人群中进行随机对照试验。
方法：前瞻性招募了43例具有长期持续的病毒后OD的连续患者。在两个嗅沟中注射ImL的PRP。使用嗅觉障碍问卷（ODQ）和阈值评估PRP注射前至6个月后嗅觉变化，歧视,和识别（TDI）测试。
结果：43例患者接受双侧PRP注射（24名女性）。患者的平均年龄为58.9±16.8岁。LPOD的平均持续时间为8.7年。注射前至注射后6个月的平均TDI从10.3±10.2显着改善为20.12±12.07（p=0.001）。平均ODQ从29.8±13.0显著降低至23.4±11.3(p=0.013)。TDI和ODQ的平均变化分别为9.8和6.4。年龄与6个月阈值得分呈负相关。
结论：PRP似乎是一种有希望的治疗策略，用于长期持续的病毒后OD。我们的发现支持在该患者人群中进行随机对照试验。
